In the age of precision medicine and increasing numbers of approaches in HNSCC treatment, CSC markers, such as ALDH, CD44, BMI‐1, and Sox2, as well as c‐Met and EGFR, yield opportunities to further stratify prognosticators and gain therapy targets [34, 55]. This evidence concerns the gene MET and head and neck squamous cell carcinoma.